About Us Direct to You Research Archives Currencies Shares Media
Monitoring Home

PRODUCT PROFILE

Latest Dublin Prices

NAME	LATEST	CHANGE
Aer Lingus	1.60	-0.02	more
BoI	0.16	0.01	more
CRH	15.48	-0.15	more
Elan	10.13	0.05	more
Glanbia	10.15	0.04	more
Grafton	5.59	-0.07	more
Greencore	0.64	-0.02	more
Ind. News	0.12	0.01	more
Ryanair	6.85	0.04	more

Shares in full

Pfizer quarterly revenues fall far short

Thursday, November 01 14:41:56

Pfizer today reported quarterly revenue well below Wall Street expectations, following the loss of patent protection on its Lipitor cholesterol fighter.

The largest U.S. drugmaker said that it had earned $3.21 billion, or 43 cents per share, in the third quarter. That compared with $3.74 billion, or 48 cents per share, in the year-earlier period, when the company recorded a $1.3 billion gain on the sale of its Capsugel business.

Excluding special items, Pfizer earned 53 cents per share. Analysts on average expected 53 cents, according to Thomson Reuters I/B/E/S.

Global sales fell 16 percent to $13.98 billion, well below Wall Street expectations of $14.64 billion. (C ) Reuters

Business World is a service of Media World Ltd. All rights reserved. While every effort has been made to ensure the accuracy of the data provided, neither Media World Ltd nor its agents or representatives will be responsible for any loss or damage on the part of users however caused. The service is for entertainment only, and no decisions, particularly investment decisions, should be taken on the basis of information supplied in the service.